GGrantIndex
← Leaderboards

Access To Advanced Health Institute

Seattle, WA

Compare ↔
$98,355,471
Total funding
32
Grants

Funding over time

peak $11.4M · FY200624
$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$94,635,244 · 30
DOD$3,720,227 · 2

By mechanism

N01$59,796,344 · 8
R01$21,399,482 · 8
U01$6,205,726 · 1
$3,720,227 · 2
R21$3,691,292 · 9
N02$2,771,836 · 1

Investigators at Access To Advanced Health Institute

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Largest grants

Adjuvant Development Program$6,010,421
N01 · FY2011 · AI
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)$5,744,095
N01 · FY2019 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS$4,091,788
N01 · FY2018 · AI
Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases$3,781,845
N01 · FY2024 · AI
Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine$3,674,481
N01 · FY2022 · AI
Adjuvant Development Program$3,643,546
N01 · FY2008 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS$3,581,021
N01 · FY2014 · AI
Advanced Development of Vaccines for Infectious Diseases$3,479,950
N01 · FY2022 · AI
A SINGLE SHOT FLU VACCINE$3,372,943
· FY2010 · Department of the Army
Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine$2,853,145
N01 · FY2021 · AI
Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases$2,815,090
N01 · FY2024 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS$2,748,153
N01 · FY2017 · AI
Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine$2,719,618
N01 · FY2018 · AI
Advanced Development of Vaccines for Infectious Diseases$2,684,251
N01 · FY2021 · AI
Adjuvant Development Program$2,219,451
N01 · FY2009 · AI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$2,017,824
U01 · FY2010 · AI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$1,717,013
U01 · FY2011 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS$1,690,338
N01 · FY2016 · AI
Advanced Development of Vaccines for Infectious Diseases$1,671,005
N01 · FY2023 · AI
Advanced Development of Vaccines for Infectious Diseases$1,566,580
N01 · FY2019 · AI